 |
26 Diseases |  |
31 Trials |
|
31 Trials |  |
1838 News |  |
| «12...6789101112131415161718 |
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial completion: Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks (clinicaltrials.gov) - Jan 15, 2016
P1, N=42, Completed, Sponsor: PharmaMar
Recruiting --> Completed
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment closed, Combination therapy, Metastases: Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). (clinicaltrials.gov) - Dec 5, 2015
P1, N=40, Active, not recruiting, Sponsor: PharmaMar
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial: PM1183-A-014-15: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (clinicaltrials.gov) - Nov 21, 2015
P1, N=100, Not yet recruiting, Sponsor: PharmaMar
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P3 trial: ATLANTIS: Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (clinicaltrials.gov) - Oct 2, 2015
P3, N=600, Not yet recruiting, Sponsor: PharmaMar
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial primary completion date, Combination therapy, Metastases: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors (clinicaltrials.gov) - Sep 24, 2015
P1, N=73, Recruiting, Sponsor: PharmaMar
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Jun 2016
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment closed, Combination therapy, Metastases: Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors (clinicaltrials.gov) - Sep 18, 2015
P1, N=60, Active, not recruiting, Sponsor: PharmaMar
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors (clinicaltrials.gov) - Aug 27, 2015
P1, N=25, Recruiting, Sponsor: PharmaMar
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Trial initiation date, Combination therapy, Metastases: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas (clinicaltrials.gov) - Aug 25, 2015
P2, N=60, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Aug 2015
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial initiation date: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors (clinicaltrials.gov) - Aug 13, 2015
P1, N=25, Not yet recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Aug 2015 Initiation date: Jun 2015 --> Sep 2015
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial completion, Trial primary completion date, Metastases: Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 12, 2015
P1, N=45, Completed, Sponsor: PharmaMar
Initiation date: Jun 2015 --> Sep 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2015
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Metastases: PM1183-B-005-14: Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors (clinicaltrials.gov) - Jul 8, 2015
P2, N=225, Recruiting, Sponsor: PharmaMar
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2015 Not yet recruiting --> Recruiting
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, Metastases: PM1183-B-005-14: Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors (clinicaltrials.gov) - May 27, 2015
P2, N=225, Not yet recruiting, Sponsor: PharmaMar
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors (clinicaltrials.gov) - May 21, 2015
P1, N=25, Not yet recruiting, Sponsor: PharmaMar
- |||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open: CORAIL: Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (clinicaltrials.gov) - May 20, 2015
P3, N=420, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, Combination therapy, Metastases: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas (clinicaltrials.gov) - May 19, 2015
P2, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial initiation date, Trial primary completion date, BRCA Biomarker, Metastases: A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer (clinicaltrials.gov) - Apr 28, 2015
P2, N=117, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Initiation date: Jun 2012 --> Dec 2012 | Trial primary completion date: Mar 2015 --> Jun 2017
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P3 trial: CORAIL: Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (clinicaltrials.gov) - Apr 20, 2015
P3, N=420, Not yet recruiting, Sponsor: PharmaMar
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment closed, Trial primary completion date, Metastases: Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 10, 2015
P1, N=50, Active, not recruiting, Sponsor: PharmaMar
Initiation date: Jun 2012 --> Dec 2012 | Trial primary completion date: Mar 2015 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial primary completion date: Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks (clinicaltrials.gov) - Oct 28, 2014
P1, N=42, Recruiting, Sponsor: PharmaMar
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016 Trial primary completion date: Nov 2013 --> Nov 2015
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial primary completion date, Metastases: Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 28, 2014
P1, N=50, Recruiting, Sponsor: PharmaMar
Trial primary completion date: Nov 2013 --> Nov 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Combination therapy, Metastases: Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors (clinicaltrials.gov) - Oct 28, 2014
P1, N=50, Recruiting, Sponsor: PharmaMar
Trial primary completion date: Sep 2014 --> Sep 2015 Not yet recruiting --> Recruiting
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial primary completion date, Combination therapy, Metastases: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors (clinicaltrials.gov) - Oct 22, 2014
P1, N=73, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Combination therapy: A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Oct 15, 2014
P2, N=120, Recruiting, Sponsor: PharmaMar
Trial primary completion date: Jun 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). (clinicaltrials.gov) - Aug 6, 2014
P1, N=40, Recruiting, Sponsor: PharmaMar
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment change, Metastases: Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 7, 2014
P1, N=50, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting N=40 --> 50
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Combination therapy, Metastases: Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors (clinicaltrials.gov) - Mar 30, 2014
P1, N=60, Recruiting, Sponsor: PharmaMar
N=40 --> 50 Not yet recruiting --> Recruiting
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open: Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks (clinicaltrials.gov) - Nov 12, 2013
P1, N=42, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors (clinicaltrials.gov) - Nov 7, 2013
P1, N=50, Not yet recruiting, Sponsor: PharmaMar
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors (clinicaltrials.gov) - Oct 24, 2013
P1, N=47, Completed, Sponsor: PharmaMar
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors (clinicaltrials.gov) - Oct 24, 2013
P1, N=73, Recruiting, Sponsor: PharmaMar
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, Combination therapy: A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Sep 24, 2013
P2, N=120, Not yet recruiting, Sponsor: PharmaMar
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors (clinicaltrials.gov) - Apr 11, 2013
P1, N=60, Recruiting, Sponsor: PharmaMar
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, BRCA Biomarker, Metastases: A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer (clinicaltrials.gov) - Mar 11, 2013
P2, N=117, Recruiting, Sponsor: PharmaMar
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial initiation date, BRCA Biomarker, Metastases: A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer (clinicaltrials.gov) - May 7, 2012
P2, N=117, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Initiation date: Mar 2012 --> Jun 2012
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, BRCA Biomarker, Metastases: A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer (clinicaltrials.gov) - Feb 1, 2012
P2, N=117, Recruiting, Sponsor: PharmaMar
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, Metastases: Study of PM01183 in platinum-resistant / refractory advanced ovarian cancer patients. Estudio de PM01183 en pacientes con c (EUDRACT) - Aug 8, 2011
P2, N=39, Ongoing, Sponsor: Pharma Mar S.A. Sociedad Unipersonal